Skip to content

Vor Biopharma VOR Other Nonoperating Income

Other Nonoperating Income at other companies

ARS Pharmaceuticals, Inc. logo
ARS Pharmaceuticals, Inc.SPRY
$1.97M-39.2%
Kiniksa Pharmaceuticals International, plc logo
Kiniksa Pharmaceuticals International, plcKNSA
$3.41M+48.9%
FCP
Four Corners Property TrustFCPT
$342K-12.8%
JBT Marel Corporation logo
JBT Marel CorporationJBTM
$2M0.0%
Zillow Group, Inc. logo
Zillow Group, Inc.ZG
$16M-27.3%
Douglas Emmett logo
Douglas EmmettDEI
$2.99M-39.2%

Other financials

Income statement

See full
Operating income-$35.2M-5.6%
Net income-$219.6M-576%
EPS (diluted)-$5.11+1.9%

Balance sheet

See full
Cash & equivalents$169.9M+239%
Total debt$2.9M-90.5%
Total equity-$150.4M-328%
Total assets$506.7M+364%

Cash flow

See full
Operating cash flow-$38.2M-23.1%
CapEx$48.0K-79.2%
Free cash flow-$38.3M-22.4%

Valuation

See full
Market cap$784.61M+2,513%
Enterprise value$617.68M+5,639%

Returns & leverage

See full
Return on equity-125.4%+671pp
Debt / equity0.5×+0.2×
Current ratio31.1×+27.3×

Where this comes from

Reported directly by Vor Biopharma in its filing.

Tagged under the XBRL concept us-gaap:OtherNonoperatingIncome.

The official record: Vor Biopharma’s 10-K, filed March 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Vor Biopharma's other nonoperating income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Vor Biopharma's other nonoperating income?
Vor Biopharma (VOR) reported other nonoperating income of $2K in Q4 2025.
What does other nonoperating income mean?
This metric represents income or expenses derived from activities outside of the company's core clinical and operational business functions. It typically includes items such as interest income, gains or losses on asset disposals, or other peripheral financial activities. Monitoring this helps investors isolate the impact of non-core financial events from the company's primary research and development performance.